Articles |

Effects of Cysteinyl-Leukotriene Receptor Antagonist, Thromboxane A2 Receptor Antagonist, and Thromboxane A2 Synthetase Inhibitor on Antigen-Induced Bronchoconstriction in Patients With Asthma FREE TO VIEW

Yasushi Obase; Terufumi Shimoda; Nobuko Matsuo; Hiroto Matsuse; Sadahiro Asai; Shigeru Kohno
Author and Funding Information

Affiliations: From the Second Department of Internal Medicine, Sasebo City General Hospital, Nagasaki, Japan,  From the Nagasaki University School of Medicine, and the Department of Internal Medicine, Sasebo City General Hospital, Nagasaki, Japan

Yasushi Obase, MD, The Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto-machi, Nagasaki 852-8501, Japan; e-mail: obadann-ngs@umin.u-tokyo.ac.jp

1998 by the American College of Chest Physicians

Chest. 1998;114(4):1028-1032. doi:10.1378/chest.114.4.1028
Text Size: A A A
Published online


Background: Leukotriene (LT) and thromboxane A2 (TXA2) receptor antagonists have been used in the treatment of asthma.

Objectives: We examined the effects of an LT receptor antagonist, TXA2 receptor antagonist, and TXA2 synthetase inhibitor on bronchoprovocation test (BPT) in patients with mild-to-moderate atopic asthma.

Methods: BPT was performed four times in each of six asthmatics. Development of the immediate asthmatic reaction (IAR) and late asthmatic reaction (LAR) was confirmed on the first BPT (BPT1). After a 7-day washout period, an LT receptor antagonist (pranlukast, 450 mg/d), TXA2 receptor antagonist (seratrodast, 80 mg/d), or TXA2 synthetase inhibitor (ozagrel, 800 mg/d) was administered orally over 7 days at random using a cross-over method (BPT2-4). Blood levels of LTB4, LTC4, LTD4, 11-dehydrothromboxane B2, eosinophil cationic protein, and histamine were measured at reaction phases of pre-BPT, IAR, and LAR.

Results: Administration of pranlukast suppressed IAR by 80.5% (p < 0.0001) and LAR by 54.6% (p = 0.0391). Ozagrel significantly suppressed IAR by 39.5% (p = 0.0413), but the fall in FEV1 was >20% (21.56 ± 4.173%). Seratrodast did not suppress IAR or LAR. Blood levels of chemical mediators did not correlate with the suppressive effects of the tested drugs.

Conclusions: The LT receptor antagonist was considered to be the most effective. LT might play a more important role in the pathogenesis of asthma than TXA2. Our data showed that measurement of blood levels of chemical mediators is not useful in identifying the pathogenic mechanisms of asthma.




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543